You may have to Search all our reviewed books and magazines, click the sign up button below to create a free account.
You asked for a new edition. Here it is, better than ever! Not only have many of the same experts in hematology and oncology returned to update their chapters, but new specialists have joined the team, rounding out this edition's detailed coverage of cancer treatment, palliative care, blood disorders, genetic counseling, and more. New to this edition are: skeletal complications of malignancy, fatigue in the cancer patient, and targeted molecular therapy. Freshen your knowledge base, study for the boards, or read for the challenge of testing yourself. - Back cover.
While patients with metastatic renal cell carcinoma (mRCC) are now living longer with improved quality of life, the success of novel therapies for mRCC has created challenges for practicing oncologists. Many patients who initially respond to targeted therapies ultimately develop progressive disease due to acquired resistance to these agents. Additionally, some patients do not respond at all to any of the currently approved targeted agents, underscoring the need for continued and concerted efforts to identify other relevant targets and pursue alternative therapeutic strategies. Part of the Oxford American Oncology Library, Renal Cell Carcinoma is a concise handbook that addresses the complex management of patients with mRCC. The book begins with a review of the epidemiology, pathology, and biology of renal cell carcinoma followed by chapters on specific targeted therapies and managing complications. The final chapters discuss supportive and integrative care and emerging therapies.
Reports for 1958-1970 include catalogues of newspapers published in each state and Union Territory.
None